Precision Care for Pulmonary Vascular Disease

Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series)

Lindsay M. Forbes, Natalie Bauer, AritraBhadra, Stefan Gräf, GustavoA.Heresi, Rachel K. Hopper, Harm J. Bogaard, Gaurav Choudhary, Kara N. Goss, Arun Jose, Yunhye Kim, Timothy Klouda, Tim Lahm, Allan Lawrie, Peter J. Leary, Jane A. Leopold, Suellen D. Oliveira, Christopher J. Rhodes, Duncan J. Stewart, Rebecca R. Vanderpool, Sasha Z. Prisco, Ruslan Rafikov, Ke Yuan, […]

Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series) Read More »

Factors influencing pulmonary arterial pressure in three related patients with Cantú syndrome: glyburide may provide precision care

Ronald W. Day, Benjamin F. CallUniversity of Utah and Primary Children’s Hospital. Portneuf Cardiology.United States Rare Disease and Orphan Drugs JournalRare Dis Orphan Drugs J 2023; DOI: 10.20517/rdodj.2023.12 AbstractA range of pulmonary arterial pressures was observed in three related patients with Cantú syndrome. The incident patient developed a moderately high pulmonary vascular resistance. Several factors

Factors influencing pulmonary arterial pressure in three related patients with Cantú syndrome: glyburide may provide precision care Read More »

Prominent renal complications associated with MMACHC pathogenic variant c.80A > G in Chinese children with cobalamin C deficiency

Xiaoyu Liu, Huijie Xiao, Yong Yao, Suxia Wang, Hongwen Zhang, Xuhui Zhong, Yanling Yang, Jie Ding, Fang WangPeking University First Hospital.China Frontiers in PediatricsFront Pediatr 2023; DOI: 10.3389/fped.2022.1057594 AbstractObjective: CblC deficiency, the most common cobalamin metabolic abnormality, is caused by pathogenic variants in the MMACHC gene. The renal complications of this disease have been described only in a small

Prominent renal complications associated with MMACHC pathogenic variant c.80A > G in Chinese children with cobalamin C deficiency Read More »

Acute vasodilator testing: An opportunity to advance the precision care of pulmonary hypertension

Meghan M. Cirulis, Lynda O. Jorgensen, Ronald W. DayUniversity of Utah and Primary Children’s Hospital.United States Respiratory Medicine Case ReportsRespir Med Case Rep 2019; 28: DOI: 10.1016/j.rmcr.2019.100911 AbstractThe pulmonary arterial pressure of a child with severe pulmonary arterial hypertension immediately normalized while breathing nitric oxide during heart catheterization at 8 years of age. Her acute pulmonary

Acute vasodilator testing: An opportunity to advance the precision care of pulmonary hypertension Read More »

Genetics dictating therapeutic decisions in pediatric pulmonary hypertension? A case report suggesting we are getting closer

Leah Stevens, Elizabeth Colglazier, Claire Parker, Elena K. Amin, Hythem Nawaytou, David Teitel, Vadiyala M. Reddy, Carrie L. Welch, Wendy K. Chung, Jeffrey R. FinemanUniversity of California San Francisco. Columbia University Irving Medical Center. United States Pulmonary CirculationPulm Circ 2022; 12: DOI: 10.1002/pul2.12033 AbstractDespite therapeutic advances over the past decades, pulmonary arterial hypertension (PAH) and related

Genetics dictating therapeutic decisions in pediatric pulmonary hypertension? A case report suggesting we are getting closer Read More »

The vascular phenotype of BPD: new basic science insights-new precision medicine approaches

Wojciech Durlak, Bernard ThébaudUniversity of Ottawa. Jagiellonian University Medical College. Poland and Canada Pediatric ResearchPediatr Res 2022; DOI: 10.1038/s41390-022-02428-7 AbstractBronchopulmonary dysplasia (BPD) is the most common complication of preterm birth. Up to 1/3 of children with BPD develop pulmonary hypertension (PH). PH increases mortality, the risk of adverse neurodevelopmental outcome and lacks effective treatment. Current vasodilator

The vascular phenotype of BPD: new basic science insights-new precision medicine approaches Read More »

Scroll to Top